会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 9. 发明申请
    • PHARMACEUTICAL COMPOSITION COMPRISING A P25/CDK5 INHIBITOR FOR PREVENTING OR TREATING A NEURODEGENERATIVE DISEASE
    • 包含P25 / CDK5抑制剂的药物组合物,用于预防或治疗神经病变疾病
    • WO2006075808A1
    • 2006-07-20
    • PCT/KR2005/000098
    • 2005-01-12
    • INJE UNIVERSITYCHUNG, Sul-HeeHA, IlhoSON, Mi-YoungLEE, Hye-Won
    • CHUNG, Sul-HeeHA, IlhoSON, Mi-YoungLEE, Hye-Won
    • A61K31/381A61P25/28
    • A61K31/381
    • A pharmaceutical composition for preventing or treating a neurodegenerative disease comprises a compound inhibiting a P25/CDK (cycline-dependent kinase 5) complex as an active ingredient. Also disclosed is a method for screening a compound capable of preventing or treating a neurodegenerative disease, which comprises the steps of a) reacting a candidate compound with a P25/CDK5 complex and beta-site APP (amyloid precursor protein)-cleaving enzyme 1 (BACEl) or treating a mammalian cell expressing P25 with the candidate compound, and measuring BACE l phosphorylation; and b) comparing the measured BACEl phosphorylation with that of a control group employing no candidate compound, and identifying a compound reducing BACEl phosphorylation compared to the control group. The compound inhibiting the P25/CDK5 complex may be useful for preventing or treating a neurodegenerative disease including Alzheimer's disease because it inhibits BACEl phosphorylation and reduces the secretion of β-amyloid and the hyperphosphorylation of Tau.
    • 用于预防或治疗神经变性疾病的药物组合物包括抑制P25 / CDK(cycline-dependent kinase 5)复合物作为活性成分的化合物。 还公开了一种筛选能够预防或治疗神经变性疾病的化合物的方法,其包括以下步骤:a)使候选化合物与P25 / CDK5复合体和β-位点APP(淀粉样蛋白前体蛋白)切割酶1( BACE1)或用候选化合物处理表达P25的哺乳动物细胞,并测量BACE1磷酸化; 和b)比较测定的BACE1磷酸化与不使用候选化合物的对照组的BACE1磷酸化,并且与对照组相比,鉴定减少BACE1磷酸化的化合物。 抑制P25 / CDK5复合物的化合物可用于预防或治疗包括阿尔茨海默病在内的神经变性疾病,因为它抑制BACE1磷酸化并降低β-淀粉样蛋白的分泌和Tau的过度磷酸化。